Cue Biopharma (CUE) closed at $18.95 on October 21, 2026, up 11.2% from the previous close, on volume of 111,553 shares (30-day average 363,315).
Data as of October 21, 2026.
Cue, Nurix, Flowers, MarketAxess, Borr: Insider Shake-Up
TipRanks (Sat, 17-Oct 9:01 AM ET)
Market Chameleon (Mon, 21-Sep 3:05 AM ET)
Globe Newswire (Sun, 20-Sep 6:00 AM ET)
PRNewswire (Mon, 24-Aug 9:05 AM ET)
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Fri, 14-Aug 4:05 PM ET)
Globe Newswire (Mon, 3-Aug 8:30 AM ET)
Market Chameleon (Fri, 15-May 4:45 AM ET)
Market Chameleon (Wed, 15-Apr 7:08 AM ET)
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.
As of October 22, 2026, CUE stock price declined to $18.31 with 2,855 million shares trading.
CUE has a beta of 4.83, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.11 to the broad based SPY ETF.
CUE has a market cap of $133.01 million. This is considered a Micro Cap stock.
Last quarter Cue Biopharma reported $8 million in Revenue and -$24.14 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$22.76.
In the last 3 years, CUE traded as high as $97.47 and as low as $4.97.
The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF, IWC, AVSC, AVTM.
CUE has underperformed the market in the last year with a price return of -26.0% while the SPY ETF gained +15.2%. CUE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.3% and -18.7%, respectively, while the SPY returned +2.6% and -1.4%, respectively.
CUE support price is $17.08 and resistance is $20.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.
